TCON TRACON Pharmaceuticals Inc (QB)

TRACON Pharmaceuticals, Inc.

124 Washington Street

Foxborough, MA 02035

October 31, 2024

VIA EDGAR

United States Securities and Exchange Commission

Division of Corporation Finance

100 F Street, N.E.

Washington, D.C. 20549

Attention: Tim Buchmiller

Re: TRACON Pharmaceuticals, Inc.

Rule 477 Application for Withdrawal of Registration Statement on Form S-1

Filed on April 12, 2024

File No. 333-278661

Ladies and Gentlemen:

Pursuant to Rule 477 under the Securities Act of 1933, as amended (the “Securities Act”), TRACON Pharmaceuticals, Inc. (the “Company”) hereby respectfully requests that, effective as of the date first set forth above or at the earliest practicable date thereafter, the Securities and Exchange Commission (the “Commission”) consent to the withdrawal of the Company’s Registration Statement on Form S-1 (File No. 333-278661) initially filed with the Commission on April 12, 2024, together with all exhibits thereto (the “Registration Statement”). The grounds upon which the Company is making this application for withdrawal are that the Company’s board of directors and stockholders have approved the liquidation and dissolution of the Company pursuant to a plan of dissolution, and accordingly the Company does not intend to proceed with the offering of the common stock proposed to be registered by the Registration Statement at this time.

The Company confirms that the Registration Statement has not been declared effective and no securities have been or will be issued or sold pursuant to the Registration Statement or the prospectus contained therein.

Pursuant to Rule 477(b) under the Securities Act, the Company understands that this request for withdrawal of the Registration Statement will be deemed granted as of the date hereof unless the Company receives notice from the Commission within 15 days of the date hereof that such request will not be granted.

The Company also requests, in accordance with Rule 457(p) under the Securities Act, that all fees paid to the Commission in connection with the filing of the Registration Statement be credited for future use for the Company’s account.

Thank you for your assistance. If you should have any questions, please contact Matthew Browne of Cooley LLP at (858) 550-6045, or in his absence, Anitha Anne at (415) 693-2250.

	Very truly yours,
	TRACON Pharmaceuticals, Inc.
	By:	/s/ Craig R. Jalbert
	Name:	Craig R. Jalbert
	Title:	President and Chief Executive Officer

---

cc:	Scott Brown, TRACON Pharmaceuticals, Inc. Matthew Browne, Cooley LLP Anitha Anne, Cooley LLP

---

---